Loading patent…
AssigneesArdan Pharma S.A.S., Universidad De La RepúBlica Oriental Del Uruguay, Institut Pasteur de Montevideo
InventorsMarcelo Rafael Hill Mongabure, Mercedes Segovia, Helena Pardo Minetti, Álvaro Mombrú, Sabina Victoria, Analia Castro, Maria Inés Varela Vega
Estimating the term…
This invention is related to an anti-tumoral composition for the treatment of neoplastic pathologies of malignant kind, and for the treatment of eg7 thymic lymphoma. Said composition comprises a TMEM176A/B inhibitor formulated in nanoparticles. This invention is also related to a method of treating neoplastic pathologies of malignant kind. Said method comprises the steps of administering to a subject a TMEM176A/B inhibitor formulated in nanoparticles.
An anti-tumoral composition, for the treatment of neoplastic pathologies of malignant kind, wherein said composition comprises a TMEM176A/B inhibitor encapsulated in Chitosan nanoparticles, wherein said TMEM176A/B inhibitor is (+)BayK8644.
An anti-tumoral composition for the treatment of eg7 thymic lymphoma, wherein said composition comprises a TMEM176A/B inhibitor encapsulated in Chitosan nanoparticles, wherein said TMEM176A/B inhibitor is (+)BayK8644.
A method of treating neoplastic pathologies of malignant kind, wherein said method comprising the steps of administering to a subject a TMEM176A/B inhibitor formulated in Chitosan nanoparticles, wherein said TMEM176A/B inhibitor is (+)BayK8644.
Dependencies are inferred from the claim text.